Closed Loop Medicine raises £13m in Series A funding led by Ananda Impact Ventures and BGF.
The financing round was co-led by Ananda Impact Ventures and BGF to accelerate platform and product development.
Closed Loop Medicine develops single prescription drug and digital therapy combination products designed to improve patient outcomes through precision dosing. The company maintains clinical programmes targeting conditions such as insomnia and hypertension.
Closed Loop Medicine has secured £13m in a Series A financing round co-led by Ananda Impact Ventures and BGF. The syndicate supporting the round includes LifeArc, Longwall, Meltwind, IQ Capital, Downing Ventures, and Cambridge Angels.
The fresh capital will be directed towards accelerating the development, registration, and commercialisation of the company's proprietary platform and precision dosing products. The firm currently has treatments in clinical development for insomnia and hypertension.
Use of funds
- 01Continue product development
Investors
Categories
About the company
Closed Loop Medicine
Closed Loop Medicine develops integrated drug and digital therapeutics to enable precision dosing.